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A B S T R A C T
Current treatment options for spinal cord injury (SCI) are scarce. One of the most promising innovative
approaches include gene-therapy, however no single gene has so far been shown to be of clinical relevance. This
study investigates the eﬃcacy of various combinations of vascular endothelial growth factor (VEGF), glial cell-
derived neurotrophic factor (GDNF), angiogenin (ANG) and neuronal cell adhesion molecule (NCAM) in rats.
Multiple therapeutic genes were administered intrathecally either via adenoviral vectors or by using genetically
modiﬁed human umbilical cord blood mononuclear cells (hUCBMCs). Following the induction of SCI, serial
assessment of cord regeneration was performed, including morphometric analysis of gray and white matters,
electrophysiology and behavioral test. The therapeutic gene combinations VEGF + GDNF + NCAM and VEGF
+ ANG+ NCAM had positive outcomes on spinal cord regeneration, with enhanced recovery seen by the cell-
based approach when compared to direct gene therapy. The eﬃcacy of the genes and the delivery methods are
discussed in this paper, recommending their potential use in SCI.
1. Introduction
Limited regeneration in the CNS is one of main obstacles for
potential treatment of neurological disorders. Delivery of recombinant
genes encoding therapeutic molecules to CNS after neurotrauma, stroke
or neurodegenerative diseases is a promising strategy to suppress
degeneration by increasing of the aﬀected neuronal cells survivability
and stimulate neuroregeneration by reconstructing glial environment,
promoting sprouting of axons and restoring interneuronal communica-
tions. The list of therapeutic genes is quite big and diverse and includes
genes that encode growth, neurotrophic, angiogenic, anti-apoptotic,
and anti-inﬂammatory factors, diﬀerent types of enzymes, and cell
adhesion molecules. With new technologies, the possibility to use
simultaneously a number of diﬀerent genes increases the success of
the therapy by ﬁnding eﬀective tandem of genes for speciﬁc CNS
disorder. Previously we have shown that intraspinal injection of
recombinant adenoviral vectors with genes of glial derived neuro-
trophic factor (GDNF) (Mukhamedshina et al., 2016), or tandem of
genes for vascular endothelial growth factor (VEGF) and angiogenin
(ANG) (Povysheva et al., 2017) can stimulate functional recovery in rat
after traumatic spinal cord injury (SCI). GDNF is considered as an
important survival factor for motorneurons and may have clinical
application for the treatment of SCI. As it was shown, the level of
GDNF mRNA increases rapidly in the nervous tissue after an injury
(Höke et al., 2000) and direct GDNF gene therapy can protect cortical
and spinal neuron (Barati et al., 2006; Tang et al., 2004), promoted
corticospinal tract regeneration and motor function improvement (Lu
et al., 2002). VEGF was initially described as a vascular permeability
factor with speciﬁc mitogenic activity for endothelial cells (Ferrara
et al., 1992). Besides angiogenic action, VEGF acts as a typical
neurotrophic factor and increases survivability of sensory (Sondell
et al., 1999) and motor (Islamov et al., 2004) neurons, promotes
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